Speakers

Andrew Philip Witty

CEO GlaxoSmithKline

Sir Andrew Philip Witty has been the Chief Executive Officer of GlaxoSmithKline S.A.E. since May 21, 2008. Sir Witty serves as the Chief Executive Officer of GlaxoSmithKline Australia Pty. Ltd. He serves as the Chief Executive Officer of Gsk Plc. He is a Venture Partner at Hatteras Venture Partners since Sept 19, 2017. He will primarily focus on the strategic positioning of Hatteras and its portfolio companies in healthcare industry. He is an Advisor to the Bill and Melinda Gates Foundation. He has been Chancellor of the University of Nottingham since January 2013 and was appointed to the UK Business Ambassador Group in January 2014. He served as the Chief Executive Officer of GlaxoSmithKline plc from May 21, 2008 to March 31, 2017. He served as the President of Pharmaceuticals Europe at GlaxoSmithKline Plc since January 2003 and also served as its Chief Executive Officer Designate since October 2007. He served as an Executive Director of GlaxoSmithKline plc from January 31, 2008 to March 31, 2017. He served as the Chief Executive Officer of GlaxoSmithKline Consumer Nigeria plc. Since 2003, he served as the President of GSK Europe and joined GSK's Corporate Executive Team. He served as the President of the European Federation of Pharmaceutical Industries and Associations until June 2013. He served as a Senior Vice President of Asia Pacific at Pharmaceuticals International since January 2001 and was responsible for its operations in Asia Pacific. He joined Glaxo UK in 1985 and has served in various senior roles in the UK, the U.S., South Africa and Singapore, including Director of Pharmacy & Distribution in Glaxo Pharmaceuticals UK, Director of Business Development of Biocompatibles Limited and International Product Manager of Glaxo Holdings PLC. He served as the Managing Director of Glaxo South Africa and Area Director of South and East Africa. He served as a Vice President and General Manager at Marketing of Glaxo Wellcome Inc. He served as an Economic Adviser to the Governor of Guangzhou, China from 2000 to 2002. He has been a Director of G1 Therapeutics, Inc., since July 13, 2017, UnitedHealth Group Incorporated since August 2017 and GlaxoSmithKline Group since January 2008. He serves on Imperial College Commercialisation Advisory Board. He serves as a Director of the Office for Strategic Coordination of Health Research. He has been a Member of Advisory Board of Synthego Corp. since September 2017. He is a Member of the UK Prime Minister's Business Advisory Group and Member of the Global Health Innovation Advisory Board, Imperial College London. He served as the Lead Non-Executive Board Member at Department for Business, Energy and Industrial Strategy from January 1, 2011 to December 2013. He served as a Director of Singapore Economic Development Board. He served as a Director of the Singapore Land Authority Board under the Ministry of Law from 2002 to 2003. In 2003, he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In the 2012 New Year Honours list, he was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry. Sir Witty holds BA in Economics from Nottingham University in the UK.